{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:40:52Z","timestamp":1792741252285,"version":"4.5.0"},"reference-count":23,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,4,1]]},"abstract":"<jats:p>Objective.\u2003To determine the safety and immunogenicity of heptavalent pneumococcal saccharide vaccine (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F) individually conjugated to CRM197 (PNCRM7), administered at 2, 4, 6, and 12 to 15 months of age.<\/jats:p><jats:p>Design.\u2003Two hundred twelve healthy 2-month-old infants were equally randomized to receive four consecutive doses of PNCRM7 or an investigational meningococcal group C conjugate vaccine, which served as a control. Concomitantly administered routine vaccines were oral polio vaccine and combined diphtheria toxoid, tetanus toxoid, and whole cell pertussis vaccine\/Haemophilus influenzae type b vaccine consisting of capsular oligosaccharides conjugated to CRM197 (DTP\/HbOC) at 2, 4, and 6 months, and either measles-mumps-rubella vaccine or HbOC at 12 to 15 months. Active safety surveillance was conducted for 3 days after each dose. Antibody concentrations to each of the 7 pneumococcal serotypes were measured by enzyme-linked immunosorbent assay prevaccination, after doses two and three, prebooster, and postbooster.<\/jats:p><jats:p>Results.\u2003Significantly fewer children experienced local reactions at the PNCRM7 injection site than at the DTP\/HbOC site. There was no increase in the incidence or severity of local reactions at the PNCRM7 site with increasing doses of vaccine. Mild to moderate postvaccination fever was common in both the PNCRM7 and control vaccine groups, however DTP\/HbOC was administered concurrently. All 7 vaccine serotypes were immunogenic. The kinetics of the immune responses were serotype-specific. After three doses of PNCRM7, between 92% to 100% of children had \u22650.15 \u03bcg\/mL of antibody, and 51% to 90% achieved a level of \u22651 \u03bcg\/mL against specific serotypes. A booster dose of PNCRM7 resulted in a brisk anamnestic response to all 7 vaccine serotypes, demonstrating effective stimulation of T-cell memory by the primary series of vaccinations.<\/jats:p><jats:p>Conclusion.\u2003Primary immunization followed by a booster dose of PNCRM7 seemed to be acceptably safe and resulted in significant rises in antibody to all 7 serotypes.<\/jats:p><jats:p>Implications.\u2003Studies to assess vaccine efficacy of PNCRM7 for prevention of systemic disease, nasopharyngeal colonization, and acute otitis media are in progress. If PNCRM7 proves to be protective, there is the potential to prevent up to 85% of invasive pneumococcal disease occurring in US children.<\/jats:p>","DOI":"10.1542\/peds.101.4.604","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:44:32Z","timestamp":1092440672000},"page":"604-611","source":"Crossref","is-referenced-by-count":297,"title":["Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants"],"prefix":"10.1542","volume":"101","author":[{"given":"Margaret B.","family":"Rennels","sequence":"first","affiliation":[{"name":"From the Center for Vaccine Development and Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland; the"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee; the"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.","family":"Keyserling","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Epidemiology, and Immunology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Reisinger","sequence":"additional","affiliation":[{"name":"Pittsburgh Pediatric Research, Pittsburgh, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Hogerman","sequence":"additional","affiliation":[{"name":"Wyeth-Lederle Vaccines and Pediatrics, West Henrietta, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dace V.","family":"Madore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ih","family":"Chang","sequence":"additional","affiliation":[{"name":"Wyeth-Lederle Vaccines and Pediatrics, West Henrietta, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Paradiso","sequence":"additional","affiliation":[{"name":"Wyeth-Lederle Vaccines and Pediatrics, West Henrietta, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Malinoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kimura","sequence":"additional","affiliation":[{"name":"Wyeth-Lederle Vaccines and Pediatrics, West Henrietta, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[1998,4,1]]},"reference":[{"key":"2021121000281524700_B1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jama.1993.03500020055031","article-title":"Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era.","volume":"269","author":"Adams","year":"1993","journal-title":"JAMA."},{"key":"2021121000281524700_B2","first-page":"545","article-title":"Progress toward elimination of Haemophilus influenzae type b disease among infants and children.","volume":"44","author":"Centers for Disease Control and Prevention","year":"1995","journal-title":"MMWR."},{"key":"2021121000281524700_B3","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.1994.03510470035031","article-title":"Emergence of drug-resistant pneumococcal infections in the United States.","volume":"271","author":"Breiman","year":"1994","journal-title":"JAMA."},{"key":"2021121000281524700_B4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00006454-199404000-00014","article-title":"Invasive pneumococci with high-level penicillin resistance at a children's hospital.","volume":"13","author":"Leggiadro","year":"1994","journal-title":"Pediatr Infect Dis J."},{"key":"2021121000281524700_B5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00006454-199509000-00004","article-title":"High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community.","volume":"14","author":"Duchin","year":"1995","journal-title":"Pediatr Infect Dis J."},{"key":"2021121000281524700_B6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/infdis\/169.1.212","article-title":"Serotypes responsible for invasive Streptococcus pneumoniae infections among children in Connecticut.","volume":"169","author":"Shapiro","year":"1994","journal-title":"J Infect Dis."},{"key":"2021121000281524700_B7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/infdis\/171.4.885","article-title":"Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978\u20131994: implications for development of a conjugate vaccine.","volume":"171","author":"Butler","year":"1995","journal-title":"J Infect Dis."},{"key":"2021121000281524700_B8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00006454-199602000-00009","article-title":"Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants.","volume":"15","author":"\u212bhman","year":"1996","journal-title":"Pediatr Infect Dis J."},{"key":"2021121000281524700_B9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00006454-199604000-00010","article-title":"Pilot trial of a pentavalent pneumococcal polysaccharide\/protein conjugate vaccine in Gambian infants.","volume":"15","author":"Leach","year":"1996","journal-title":"Pediatr Infect Dis J."},{"key":"2021121000281524700_B10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1086\/514063","article-title":"Immunization of infants with pentavalent pneumococcal-CRM197 conjugate vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered HbOC and DTP vaccines.","volume":"176","author":"Daum","year":"1997","journal-title":"J Infect Dis."},{"key":"2021121000281524700_B11"},{"key":"2021121000281524700_B12"},{"key":"2021121000281524700_B13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archpedi.1983.02140350024007","article-title":"Pneumococcal vaccine in normal children: primary and secondary vaccination.","volume":"137","author":"Lawrence","year":"1983","journal-title":"Am J Dis Child."},{"key":"2021121000281524700_B14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/cdli.2.5.590-597.1995","article-title":"Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S.","volume":"2","author":"Quataert","year":"1995","journal-title":"Clin Diagn Lab Immunol."},{"key":"2021121000281524700_B15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1542\/peds.96.3.600","article-title":"The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data.","volume":"96(suppl)","author":"Reed","year":"1995","journal-title":"Pediatrics."},{"key":"2021121000281524700_B16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3181\/00379727-157-40010","article-title":"Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants.","volume":"157","author":"Borgono","year":"1978","journal-title":"Proc Soc Exp Biol Med."},{"key":"2021121000281524700_B17","first-page":"1","article-title":"Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine.","volume":"42","author":"Advisory Committee on Immunization Practices","year":"1993","journal-title":"MMWR."},{"key":"2021121000281524700_B18","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of H influenzae type b.","volume":"147","author":"Ka\u0308yhty","year":"1983","journal-title":"J Infect Dis."},{"key":"2021121000281524700_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/153.1.1","article-title":"Passive immunization against disease due to Haemophilus influenzae type b: concentration of antibody to capsular polysaccharide in high-risk children.","volume":"153","author":"Ambrosino","year":"1986","journal-title":"J Infect Dis."},{"key":"2021121000281524700_B20","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1093\/infdis\/165-Supplement_1-S129","article-title":"Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease.","volume":"165(suppl 1)","author":"Siber","year":"1992","journal-title":"J Infect Dis."},{"key":"2021121000281524700_B21","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/infdis\/174.6.1271","article-title":"Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine.","volume":"174","author":"Dagan","year":"1996","journal-title":"J Infect Dis."},{"key":"2021121000281524700_B22","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1073\/pnas.94.12.6571","article-title":"Vaccination against colonizing bacteria with multiple serotypes.","volume":"94","author":"Lipsitch","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"2021121000281524700_B23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/infdis\/171.4.890","article-title":"Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo.","volume":"171","author":"Barnes","year":"1995","journal-title":"J Infect Dis."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/101\/4\/604\/828366\/604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/101\/4\/604\/828366\/604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:32:08Z","timestamp":1682746328000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/101\/4\/604\/61994\/Safety-and-Immunogenicity-of-Heptavalent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,4,1]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[1998,4,1]]},"published-print":{"date-parts":[[1998,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.101.4.604","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[1998,4,1]]}}}